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Low Incidence of Neuroleptic
Malignant Syndrome
Associated With Paliperidone
Palmitate Long-Acting
Injectable
A Database Report and
Case Study
To the Editors:
N euroleptic malignant syndrome (NMS)is a rare, potentially fatal, and idiosyn-
cratic adverse reaction that occurs in ap-
proximately 0% to 3% of individuals taking
conventional antipsychotic medication.1–4
This syndrome usually presents with rigid-
ity, abrupt onset of fever, autonomic dys-
regulation, and altered mental status.1 Other
symptoms associated with NMS include
tremor, extrapyramidal symptoms, altered
electrocardiogram, and laboratory abnor-
malities, such as elevated serum creatine
kinase (CK), impaired liver function tests,
leukocytosis, electrolyte abnormalities, re-
nal impairment, and altered coagulation
(Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition criteria for NMS).
The primary cause of NMS is thought to be
dopamine receptor blockade, particularlywith
the use of antipsychotic medications.5
Available evidence of NMS associated
with oral antipsychotics suggests that sec-
ond-generation oral antipsychotics have a
lower incidence of NMS, with less severity
and infrequent fatal outcomes, compared
with first-generation oral antipsychotics.6–9
In contrast, little is known about the fre-
quency and management of NMS associ-
ated with long-acting injectables (LAIs)
prescribed for treatment of schizophrenia,
including LAIs of paliperidone (9-OH me-
tabolite of risperidone) such as paliperidone
palmitate 1-monthly (PP1M) and 3-monthly
(PP3M). The concern about NMS develop-
ment due to LAI antipsychotics and the
associated hospitalization, morbidity, and
mortality limits LAI usage in clinical prac-
tice in the United States. Also, LAIs may
be underutilized because of the perception
that an LAI antipsychotic is not quickly
cleared from the patient's system and may
hinder NMSmanagement. This letter dis-
cusses the incidence and nature of NMS
associated with paliperidone palmitate
LAI formulations identified from Janssen
clinical trial databases of PP1M and PP3M
and the treatment implications for NMS
associated with second-generation anti-
psychotic LAI formulations.
All cases of NMS in the Janssen
PP1M and PP3M phases 1 to 3 clinical trial
databases were searched cumulatively through
April 30, 2018. Specific Medical Dictionary
for Regulatory Activities (MedDRA, version
16.0) preferred terms used in the search for
NMS are listed in Table 1. Individual case re-
view was performed for each patient who
experienced at least one of the terms
listed. In each identified case, reports of
treatment-emergent adverse events, vital
signs, physical examination, laboratory
findings, and clinical management of
the event were reviewed. The incidence rate
ofNMSwas calculated based on the number
of identified cases divided by the total per-
son-time at risk.
The Janssen clinical trial database
search identified 1 credible case of NMS
from 5008 patients who received 1 or more
injection of PP1M or PP3M and were
followed for 2271.6 patient-years. A sec-
ond case of NMSwas identified but was not
included in this study because the pa-
tient (from a single-dose pharmacokinetics
study in Japan; NCT01606254) was diag-
nosed with NMS more than 3 months (ap-
proximately 3 half-lives) after the last
injection of PP1M. Furthermore, the patient
was receiving other antipsychotics at the
time of diagnosis of NMS. The resulting
raw incidence of NMS was 0.020% (95%
TABLE 1. List of Preferred Terms Used in the Search for NMS in the Janssen Clinical
Trial Database
Hyperthermia malignant Delirium
NMS Depressed level of consciousness
Serotonin syndrome Disorientation
Body temperature increased Extrapyramidal disorder
Hyperpyrexia Heart rate abnormal
Pyrexia Heart rate increased
Catatonia Hyperhidrosis
Dyskinesia Hypertension
Dystonia Hypotension
Freezing phenomenon Labile blood pressure
Hyperkinesia Labile hypertension
Hypertonia Leukocytosis
Muscle necrosis Loss of consciousness
Muscle rigidity Muscle enzyme increased
Oculogyric crisis Myoclonus
Oculogyration Myoglobin blood increased
Opisthotonus Myoglobin blood present
Rhabdomyolysis Myoglobin urine present
Altered state of consciousness Myoglobinemia
Autonomic nervous system imbalance Myoglobinuria
Blood creatine phosphokinase abnormal Parkinsonian crisis
Blood creatine phosphokinase increased Parkinsonian rest tremor
Blood creatine phosphokinase MM increased Parkinsonism
Blood pressure abnormal Parkinson's disease
Blood pressure decreased Stupor
Blood pressure fluctuation Tachycardia
Blood pressure increased Tremor
Cardiovascular insufficiency Unresponsive to stimuli
Coma White blood cell count abnormal
Confusional state White blood cell count increased
Consciousness fluctuating
Preferred terms used were from Medical Dictionary for Regulatory Activities (MedDRA,
version 16.0).
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confidence interval, 0.0028%–0.14%), and
the incidence rate was 0.044% (95% confi-
dence interval, 0.042%–0.13%) per year.
CASE REPORT
The patient identified with NMS was a
55-year-old, white man with a diagnosis
of schizophrenia, paranoid type, since17years
of age who was enrolled in a randomized,
double-blind, parallel-group study of flexi-
bly dosed PP1Mversus Risperdal CONSTA
(Risperidone LAI).10 The patient had 4 prior
hospitalizations for psychosis and a history
of smoking, had no alcohol or drug abuse,
and had no other significant medical his-
tory reported. The physical examination at
screening was unremarkable, except for re-
duced hearing in the left ear, cerumen in
both ear canals, gum disease, cavities, and
a body mass index of 25.7 kg/m2 (over-
weight). The patient was previously treated
with flupenthixol decanoate 15 mg in-
tramuscularly every 2 weeks for 6 years,
which was discontinued 22 days prior to
randomization. From day −6 to day −3 of
the screening period, the patient was given
paliperidone extended release 3 mg for oral
tolerability testing. On days 1 and 8 of the
double-blind period, the patient received
an injection of 50 mg eq PP1M in the
gluteal muscle. A predose pharmacoki-
netic plasma sample was collected on
day 1, and paliperidone levels were below
the limit of quantification.
On day 15, the patient was hospital-
ized for confused mental state and had
experienced a fever (38.8°C) and little
rigidity and had “trouble relaxing” his
muscles. The diagnosis of mild NMS was
made, and laboratory results showed ele-
vated levels of CK (5824 U/L [reference
range, 55–197 U/L]) and hepatic enzymes,
including aspartate transaminase (128 U/L
[reference range, 12–45 U/L]) and alanine
transaminase (91 U/L [reference range,
7–40 U/L]). Blood pressure and pulse rate
were normal.
On day 16, lorazepam 0.5 to 1 mg/d as
a rescue medication was initiated and con-
tinued as needed for 2 days, and ciproflox-
acin 500mg twice daily for 6 dayswas given
for suspected infection that was later
ruled out. Treatment with PP1M was
discontinued on day 19 (last dose was on
day 8), and the patient was withdrawn from
the study because of the serious treatment-
emergent adverse event of NMS. On
day 20, the CK level was 860 U/L, alanine
transaminase was 52 U/L, and aspartate
transaminase was 49 U/L. Benztropine 1
to 2 mg/d was given from days 19 to 26,
then the dose was tapered and discontinued
over 2 days. Flupenthixol decanoate 15 mg
intramuscularly every 2 weeks was resumed
on day 23. The pyrexia was treated with
acetaminophen as needed. No additional
treatment was given for dizziness, psychotic
disorder, elevated liver enzymes, or elevated
CK levels. On day 28, the patient went on a
“leave of absence” from the hospital as he
was reported to have done reasonably well
but returned to the hospital on day 34 after
feeling unwell, with disorientation. The
patient had fever of 38.5°C on day 34, but
his temperature soon returned to normal
(patient's home was not air conditioned,
and the city of residence was warm at that
time). After all investigations were normal,
the patient went on a second leave of ab-
sence from days 36 to 46. The patient was
discharged from the hospital on day 46 fol-
lowing complete recovery.
DISCUSSION
From data of 5008 patients analyzed in the
Janssen clinical trial database for NMS
with PP1M and PP3M, a single case of
NMS associated with PP1M LAI was
identified. The most common manifesta-
tions of NMS, including altered mental
state, muscle rigidity, fever, and elevated
CK (>1000 U/L), were reported in this
case. The severity of NMS appeared to be
mild, and the patient recovered completely.
This database review illustrates the low
propensity for NMS events during PP1M
or PP3M treatment and successful
management of this complication in
the single case identif ied with symp-
tomatic treatment.
Given that NMS is a known and rare
adverse event associated with use of anti-
psychotics, the investigator judged that
the etiology of NMS was possibly related
to PP1M. However, the patient was also
receiving flupenthixol decanoate 15 mg
intramuscularly every 2 weeks (variable
half-life between 3 weeks and 3 months)
for 6 years prior to randomization, which
was discontinued 22 days before PP1M
administration. Thus, it is possible that ini-
tiation of NMS on day 15 cannot be attrib-
uted solely to PP1M, but rather could be
related to a combined effect of both LAI
antipsychotic agents (flupenthixol decanoate
and PP1M). Also, worsening of symptoms
on day 34 could likely be related to the
flupenthixol depot given on day 23, further
supporting the additive effect of the 2 drugs.
Findings from a retrospective study also
showed that the use of depot flupenthixol
was significantly associated with in-
creased risk of NMS.11 In the present case,
oral tolerability medication (paliperidone
extended release), although below limit of
quantification at baseline, may also be a
contributory factor.
Potential limitations of this study in-
clude possible underreporting of adverse
drug reaction, inadequate sensitivity of the
search method, and relatively short follow-up
time of patients (on average, ~5.4 months).
In summary, based on the search
conducted in the Janssen clinical trial da-
tabase, the occurrence of NMS events as-
sociated with PP1M or PP3Mwas very low
(4/10,000 patient-years); clinicians must,
however, be cautious to identify potential
NMS symptoms after administration of LAI
antipsychotics, especially when patients
have been recently taking long-acting first-
generation antipsychotics. The presented
case indicates that NMS can be managed
symptomatically even when the patient is
on an LAI antipsychotic, and it underscores
the importance of early detection and phar-
macological intervention in preventing the
progression of this potentially life-threatening
complication of antipsychotic use.
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Effects of Curcumin on
Cognitive Functioning and
Inflammatory State in
Schizophrenia
A Double-Blind,
Placebo-Controlled Pilot Trial
To the Editors:
C urcumin, derived from turmeric root,is a polyphenol with antioxidant and
anti-inflammatory properties.1,2 To our knowl-
edge, only 2 studies have tested the effec-
tiveness of add-on curcumin in patients with
schizophrenia.2,3 In an open-label study,
1 g/d of curcumin (n = 7) and 4 g/d of
curcumin (n = 8) improved overall neuro-
cognitive index over 12 weeks. More recently,
a randomized, double blind, placebo-controlled
study showed that 360 mg/d of curcumin
(n = 17) increased brain-derived neuro-
trophic factor levels compared with placebo
(n = 19) after an 8-week trial. Although this
study did not show any significant changes
in clinical symptoms and cognitive func-
tioning, improvement on brain-derived neu-
rotrophic factor levels suggested possible
long-term benefits of curcumin in cogni-
tion and clinical symptoms.2
We tested the effects of add-on curcumin
for the treatment of cognitive impairment
in schizophrenia in an 8-week randomized,
double-blind, placebo-controlled, parallel,
fixed-dose pilot clinical trial. A total of 12
outpatients with schizophrenia were random-
ized to curcumin (180 mg/d) or placebo in a
1:1 ratio. Written informed consent was
obtained from all participants. A commercially
available surface-controlledwater-soluble form
of 300 mg of curcumin (30% formulation:
90 mg pure curcumin) or matching placebo
capsules were provided by Theravalues
Corporation (Tokyo, Japan). Study proto-
col was approved by institutional review
board (Yale HIC number 1412015121)
and registered on ClinicalTrials.gov
(NCT02476708). We monitored medica-
tion adherence by means of pill count
method and patient reports.
The primary outcome measure was
between-group changes in Measurement and
Treatment Research to Improve Cognition
in Schizophrenia (MATRICS) Consensus
Cognitive Battery.4 Secondary outcomes in-
cluded changes in inflammatory markers (in-
terleukin 6 [IL-6], tumor necrosis factor α, and
high-sensitive C-reactive protein [hs-CRP]) and
clinical outcomes (Positive andNegative Symp-
tom Scale [PANSS], Calgary Depression Scale
for Schizophrenia, and The Committee of Clin-
ical Investigations (UKU) side effect scale).
All statistical analyses were performed
in SPSS Statistics version 24.0 (IBM, NY).
Baseline differences and treatment effect
in clinical symptoms, cognitive functioning,
and inflammatory markers were assessed
with nonparametric tests. Pearson χ2 analy-
sis and Fisher exact tests were used for all
categorical variables.
The study sample (9 male, 3 female)
mostly consisted of chronic schizophrenia
patients with mean ± SD duration of illness
21.66 ± 14.84 years (range, 5–51 years).
Mean ± SD age of the total sample was
41.33 ± 12.73 years, and education level
was 12.33 ± 2.42 years. At baseline, no sig-
nificant difference was found in sample
characteristics, inflammatory markers, and
clinical outcomes between treatment arms.
Table 1 summarizes changes in inflamma-
tory markers, clinical outcomes, and cogni-
tive functioning. Compared with placebo,
add-on curcumin treatment significantly
improved working memory (Z = 2.200,
P = 0.028) and reduced IL-6 levels
(Z = 2.402, P = 0.016). No significant ef-
fect of curcumin on PANSS and Calgary
Depression scores was found. No signifi-
cant adverse events were reported during
the study. The majority of the patients re-
ported that they took the medications as
prescribed. Only 2 patients returned 10
capsules in total during the whole study pe-
riod (4 curcumin and 6 placebo capsules).
In this pilot study, we found that add-on
curcumin improved working memory in pa-
tients with schizophrenia. Add-on curcumin
also reduced IL-6 levels after 8 weeks of
treatment. Although improvements in other
cognitive domains, negative symptoms, and
total PANSS scorewere observed with add-
on curcumin, these changes did not reach
statistical significance.
To a degree, our findings are in linewith
previous studies. In an open-label study,
Woodbury-Farina et al3 reported improve-
ment in cognitive functioning and negative
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